Trials that use: Hazard ratio
New to this method? Read the tutorial →
334 results
- PROfoundIndependent statistical analysis of the PROfound phase 3 trial of olaparib versus investigators' choice of enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer, including trial design, time-to-event and response…
- PROpelIndependent statistical analysis of the PROpel phase 3 trial of olaparib plus abiraterone in men with metastatic castration-resistant prostate cancer, including randomized trial design, radiological progression-free survival, overall survival, secondary time-to-event endpoints,…
- PROSPERIndependent statistical analysis of the phase 3 PROSPER trial of enzalutamide versus placebo in nonmetastatic castration-resistant prostate cancer, including metastasis-free survival, secondary time-to-event endpoints, PSA response, statistical methodology, and interpretation.
- QUAZAR AML-001Independent statistical analysis of QUAZAR AML-001, a randomized phase 3 trial of oral azacitidine plus best supportive care versus placebo plus best supportive care as maintenance therapy in acute myeloid leukemia in…
- RAINBOWIndependent statistical analysis of the phase 3 RAINBOW trial of ramucirumab plus paclitaxel versus placebo plus paclitaxel in metastatic gastric adenocarcinoma, including survival, response, quality-of-life, safety, and statistical methodology.
- RATIONALE-301Independent statistical analysis of RATIONALE-301, a randomized phase 3 trial of tislelizumab versus sorafenib in participants with unresectable hepatocellular carcinoma, including overall survival, response, progression, quality of life, and the trial's non-inferiority…
- RATIONALE-303Independent statistical analysis of RATIONALE-303, a randomized phase 3 trial comparing tislelizumab with docetaxel in second- or third-line non-small cell lung cancer, including overall survival, response, progression-free survival, quality of life, and…
- RE-COVER IIIndependent statistical analysis of RE-COVER II, a randomized phase 3 trial comparing dabigatran etexilate with warfarin for treatment of acute symptomatic venous thromboembolism, including non-inferiority and time-to-event analyses.
- RE-LYComplete statistical analysis of the RE-LY phase 3 trial of dabigatran versus warfarin, including randomized trial design, time-to-event endpoints, Cox proportional-hazards analyses, non-inferiority and superiority comparisons, safety, and statistical interpretation.
- RE-SPECT ESUSIndependent statistical analysis of RE-SPECT ESUS, the randomized phase 3 trial of dabigatran etexilate versus aspirin for secondary stroke prevention after embolic stroke of undetermined source. Includes trial design, time-to-event endpoints, Cox…
- REACHIndependent statistical analysis of the phase 3 REACH trial of ramucirumab plus best supportive care versus placebo plus best supportive care as second-line treatment for hepatocellular carcinoma after sorafenib.
- REACH-2Independent statistical analysis of REACH-2, a randomized phase 3 trial of ramucirumab plus best supportive care versus placebo plus best supportive care in hepatocellular carcinoma with elevated baseline alpha-fetoprotein.
- REACTComplete statistical analysis of the REACT trial (NCT01329029), evaluating roflumilast versus placebo in patients with chronic obstructive pulmonary disease treated with fixed LABA and inhaled glucocorticosteroid combinations.
- RECOURSEIndependent statistical analysis of the phase 3 RECOURSE trial of TAS-102 versus placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies, including trial design, time-to-event endpoints, hazard ratios, confidence intervals,…
- RED-HFIndependent statistical analysis of the RED-HF phase 3 trial of darbepoetin alfa in heart failure, including trial design, time-to-event endpoints, hazard ratios, KCCQ analyses, safety, methodology, and statistical interpretation.
- REDUCE-ITComplete statistical analysis of REDUCE-IT (NCT01492361), a randomized phase 3 trial of AMR101 versus placebo in high-risk patients with cardiovascular disease and hypertriglyceridemia on statin therapy.
- RELATIVITY-047Independent statistical analysis of RELATIVITY-047, evaluating relatlimab plus nivolumab versus nivolumab alone in participants with advanced melanoma, including trial design, progression-free survival, statistical methodology, interpretation, and limitations.
- RESORCEIndependent statistical analysis of the phase 3 RESORCE trial of regorafenib versus placebo in hepatocellular carcinoma, including overall survival, time to progression, progression-free survival, tumor response, statistical methodology, and interpretation.
- RESPIRE 1Independent statistical analysis of RESPIRE 1, a randomized phase 3 trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis, including time-to-exacerbation and exacerbation-rate analyses.
- RESPIRE 2Complete statistical analysis of the RESPIRE 2 phase 3 trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, Wald testing, and…
- REWINDComplete statistical analysis of the REWIND phase 3 trial of dulaglutide versus placebo in type 2 diabetes and cardiovascular disease, including its randomized design, time-to-event endpoints, Cox proportional-hazards analysis, cardiovascular outcomes, and…
- ROCKET AFIndependent statistical analysis of ROCKET AF, the randomized phase 3 trial of rivaroxaban versus warfarin for prevention of stroke and non-CNS systemic embolism in patients with non-valvular atrial fibrillation.
- RTOG 0617Independent statistical analysis of RTOG 0617, evaluating radiation therapy dose and cetuximab with chemotherapy in newly diagnosed unresectable stage III non-small cell lung cancer, with emphasis on survival, competing risks, safety, and…
- RTOG 0825Independent statistical analysis of RTOG 0825, a randomized phase 3 trial of temozolomide and radiation therapy with or without bevacizumab in patients with newly diagnosed glioblastoma.
- RUXCOVIDIndependent statistical analysis of the phase 3 RUXCOVID trial of ruxolitinib versus placebo in patients with COVID-19 associated cytokine storm, including the primary composite endpoint, secondary outcomes, statistical methods, safety, and interpretation.
- RxPONDERIndependent statistical analysis of the randomized phase 3 RxPONDER trial, including its invasive disease-free survival endpoint, Cox proportional-hazards analyses, menopausal-status interaction, post-hoc distant relapse-free survival results, safety, and statistical interpretation.
- S-TRACIndependent statistical analysis of the S-TRAC phase 3 trial of sunitinib versus placebo in patients at high risk of recurrent renal cell cancer, including disease-free survival, overall survival, trial design, Cox modeling,…
- SCOREDIndependent statistical analysis of SCORED (NCT03315143), a randomized phase 3 trial of sotagliflozin versus placebo in participants with type 2 diabetes and moderate renal impairment at cardiovascular risk. Includes the primary cardiovascular…
- SELECTAn independent statistical analysis of the SELECT phase 3 trial of semaglutide versus placebo in patients with overweight or obesity, including trial design, the primary time-to-event endpoint, Cox proportional-hazards analysis, and interpretation.
- SELECTComplete statistical analysis of SELECT (NCT01321554), the phase 3 randomized, double-blind, placebo-controlled trial of lenvatinib in 131I-refractory differentiated thyroid cancer, including progression-free survival, statistical methodology, safety, and interpretation.
- SEQUOIAIndependent statistical analysis of the phase 3 SEQUOIA trial comparing zanubrutinib with bendamustine plus rituximab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, including its progression-free survival analysis and statistical…
- SERAPHINIndependent statistical analysis of SERAPHIN, the randomized phase 3 trial of macitentan in symptomatic pulmonary arterial hypertension, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank testing, and interpretation.
- SHAPEIndependent statistical analysis of the SHAPE trial comparing radical versus simple hysterectomy with pelvic lymph node dissection for low-risk early stage cervical cancer, including its non-inferiority endpoint, time-to-event analyses, confidence intervals, and…
- SHARPIndependent statistical analysis of SHARP, the randomized phase 3 study of sorafenib versus placebo in patients with advanced hepatocellular carcinoma, including its overall survival and symptomatic progression endpoints, stratified log-rank methodology, interim…
- SHIFTComplete statistical analysis of SHIFT, a randomized phase 3 trial evaluating ivabradine versus placebo in patients with chronic heart failure, including Cox proportional-hazards methods, hazard ratios, confidence intervals, p-values, safety, and statistical…
- SIGNIFYIndependent statistical analysis of SIGNIFY (NCT02446990), a randomized phase 3 trial of ivabradine versus placebo in patients with stable coronary artery disease without clinical heart failure, including Cox proportional-hazards analyses and interpretation…
- SKYSCRAPER-02Independent statistical analysis of SKYSCRAPER-02, a randomized phase 3 trial of tiragolumab plus atezolizumab with carboplatin and etoposide versus placebo plus atezolizumab with carboplatin and etoposide in untreated extensive-stage small cell lung…
- SKYSCRAPER-06Independent statistical analysis of SKYSCRAPER-06, evaluating tiragolumab plus atezolizumab and chemotherapy versus pembrolizumab plus chemotherapy in previously untreated advanced non-squamous NSCLC, with detailed interpretation of PFS, OS, response, quality-of-life, and safety analyses.
- SOCRATESIndependent statistical analysis of the SOCRATES phase 3 trial of ticagrelor versus acetylsalicylic acid after acute ischaemic stroke or transient ischaemic attack, including endpoint definitions, Cox and logistic regression methods, efficacy results,…
- SOFTIndependent statistical analysis of the SOFT phase 3 trial of tamoxifen, tamoxifen plus ovarian function suppression, and exemestane plus ovarian function suppression in premenopausal women with hormone-responsive breast cancer.
- SOLAR-1Independent statistical analysis of the SOLAR-1 phase 3 trial of alpelisib plus fulvestrant in men and postmenopausal women with advanced breast cancer that progressed on or after aromatase inhibitor treatment.
- SOLEComplete statistical analysis of the SOLE phase 3 trial of continuous versus intermittent letrozole in postmenopausal women with hormone receptor-positive, lymph node-positive, early-stage breast cancer after prior hormone therapy.
- SOLO1Complete statistical analysis of SOLO1, a randomized phase 3 trial of olaparib maintenance monotherapy versus placebo in BRCA-mutated advanced ovarian cancer following first-line platinum-based chemotherapy.
- SOLOIST-WHFIndependent statistical analysis of SOLOIST-WHF (NCT03521934), evaluating sotagliflozin versus placebo in participants with type 2 diabetes and worsening heart failure. Includes trial design, registered endpoints, Cox, ANCOVA and MMRM methodology, reported results,…
- SONARIndependent statistical analysis of the phase 3 SONAR trial of atrasentan versus placebo in diabetic nephropathy, including the composite renal endpoint, hazard ratios, confidence intervals, p-values, trial design, and statistical methodology.
- SOPHIAIndependent statistical analysis of the SOPHIA phase 3 trial of margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in HER2-positive metastatic breast cancer, including its randomized design, time-to-event endpoints, hazard ratios, confidence intervals,…
- SPARTANIndependent statistical analysis of the phase 3 SPARTAN trial of apalutamide versus placebo in men with non-metastatic castration-resistant prostate cancer, including metastasis-free survival, time to metastasis, progression-free survival, statistical methodology, safety, and…
- SPLASHIndependent statistical analysis of the phase 3 SPLASH trial evaluating [Lu-177]-PNT2002 in metastatic castration-resistant prostate cancer, including randomized design, radiographic progression-free survival, hazard-ratio methodology, and statistical interpretation.
- SPOTLIGHTComplete statistical analysis of the randomized phase 3 SPOTLIGHT trial of zolbetuximab plus chemotherapy versus placebo plus chemotherapy in adults with gastric or gastroesophageal junction adenocarcinoma, including progression-free survival, overall survival, response,…
- STARSCAPEIndependent statistical analysis of the STARSCAPE phase 3 trial of zinpentraxin alfa in idiopathic pulmonary fibrosis, including trial design, endpoints, randomized efficacy analysis, time-to-event methods, safety, limitations, and statistical interpretation.